Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer
/PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by...
Source: prnewswire.com
Clinical Genomics Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Genomics Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Genomics Program Today - Breaking & Trending Today
FDA Greenlights Veopoz, the First Treatment for CHAPLE Disease
The FDA has approved Veopoz (pozelimab-bbfg) for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.
Source: empr.com
REGENERON PHARMACEUTICALS, INC. - VEOPOZ RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE
TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients 1 year of age and older with...
Source: marketscreener.com
Veopoz (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
18.08.2023 - CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the ...
Source: wallstreet-online.de
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by...
Source: marketscreener.com